Propyphenazone

Identification

Generic Name

Propyphenazone

DrugBank Accession Number

DB13524

Background

Not Available

Type

Small Molecule

Groups

Experimental

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Propyphenazone (DB13524)

×

Close

Weight

Average: 230.311
Monoisotopic: 230.141913208

Chemical Formula

C₁₄H₁₈N₂O

Synonyms

• 1-Phenyl-2,3-dimethyl-4-isopropyl-3-pyrazolin-5-one
• 1-Phenyl-2,3-dimethyl-4-isopropylpyrazol-5-one
• 4-Isopropyl-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one
• 4-Isopropylantipyrine
• Isopropylantipyrine
• Isopropylphenazone
• Propifenazona
• Propyphenazone
• Propyphenazonum

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination for symptomatic treatment of	Headache	Combination Product in combination with: Butalbital (DB00241), Caffeine (DB00201)	••••••••••••			•••••••••••• ••••••• ••••••
Used in combination for symptomatic treatment of	Pain	Combination Product in combination with: Butalbital (DB00241), Caffeine (DB00201)	••••••••••••			•••••••••••• ••••••• ••••••
Used in combination for symptomatic treatment of	Pain, menstrual	Combination Product in combination with: Caffeine (DB00201), Butalbital (DB00241)	••••••••••••			•••••••••••• ••••••• ••••••
Used in combination for symptomatic treatment of	Rheumatism	Combination Product in combination with: Caffeine (DB00201), Butalbital (DB00241)	••••••••••••			•••••••••••• ••••••• ••••••
Used in combination for symptomatic treatment of	Rheumatism, muscular	Combination Product in combination with: Butalbital (DB00241), Caffeine (DB00201)	••••••••••••			•••••••••••• ••••••• ••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Propyphenazone may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abciximab	The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Abciximab.
Acebutolol	Propyphenazone may decrease the antihypertensive activities of Acebutolol.
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Propyphenazone.
Acemetacin	The risk or severity of adverse effects can be increased when Propyphenazone is combined with Acemetacin.

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Yoshipyrin

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Adolomed 250 mg/300 mg/50 mg Tabletten	Propyphenazone (250 mg) + Acetaminophen (300 mg) + Caffeine (50 mg)	Tablet	Oral	Kwizda Pharma Gmb H	1986-08-22	Not applicable
ALJIL 150 MG/300 MG/50 MG TABLET, 20 ADET	Propyphenazone (150 mg) + Acetaminophen (300 mg) + Caffeine (50 mg)	Tablet	Oral	RECORDATİ İLAÇ SAN. VE TİC. A.Ş.	1983-08-23	Not applicable
BIOPTAN DRAJE, 30 ADET	Propyphenazone (250 mg) + Caffeine (50 mg)	Tablet, coated	Oral	BİOFARMA İLAÇ SAN. VE TİC. A.Ş.	1985-01-04	Not applicable
CISTALGAN	Propyphenazone (250 MG) + Flavoxate (200 MG)	Tablet, coated	Oral	Viatris Healthcare Limited	2014-07-08	Not applicable
DERMAN 300/100/50 MG KAŞE, 1 KAŞE	Propyphenazone (100 mg) + Acetaminophen (300 mg) + Caffeine (50 mg)	Powder	Oral	DERMAN İLAÇ SAN.VE TİC. A.Ş.	1983-10-10	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Geworin	Propyphenazone (150 mg/1) + Acetaminophen (300 mg/1)	Tablet	Oral	Lydia Co., Ltd.	2023-02-11	Not applicable
PANALGINE TABLET, 30 ADET	Propyphenazone (150 mg) + Acetaminophen (300 mg) + Caffeine (30 mg)	Tablet	Oral	ATABAY İLAÇ FABRİKASI A.Ş.	2013-01-29	Not applicable
PAROL PLUS TABLET, 30 ADET	Propyphenazone (150 mg) + Acetaminophen (250 mg) + Caffeine (50 mg)	Tablet	Oral	ATABAY KİMYA SAN. VE TİC. A.Ş.	2013-01-29	Not applicable

Categories

ATC Codes

N02BB74 — Propyphenazone, combinations with psycholeptics

• N02BB — Pyrazolones
• N02B — OTHER ANALGESICS AND ANTIPYRETICS
• N02 — ANALGESICS
• N — NERVOUS SYSTEM

N02BB54 — Propyphenazone, combinations excl. psycholeptics

• N02BB — Pyrazolones
• N02B — OTHER ANALGESICS AND ANTIPYRETICS
• N02 — ANALGESICS
• N — NERVOUS SYSTEM

N02BB04 — Propyphenazone

• N02BB — Pyrazolones
• N02B — OTHER ANALGESICS AND ANTIPYRETICS
• N02 — ANALGESICS
• N — NERVOUS SYSTEM

Drug Categories

• Agents causing hyperkalemia
• Agents that produce hypertension
• Analgesics
• Analgesics, Non-Narcotic
• Anti-Inflammatory Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Antirheumatic Agents
• Nephrotoxic agents
• Nervous System
• Non COX-2 selective NSAIDS
• Peripheral Nervous System Agents
• Pyrazoles
• Pyrazolones
• Sensory System Agents

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Azoles

Sub Class

Pyrazoles

Direct Parent

Phenylpyrazoles

Alternative Parents

Pyrazolones / Benzene and substituted derivatives / Vinylogous amides / Heteroaromatic compounds / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives

show 1 more

Substituents

Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Phenylpyrazole / Pyrazolinone / Vinylogous amide

show 6 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

pyrazolone (CHEBI:135538)

Affected organisms

Not Available

Chemical Identifiers

UNII

OED8FV75PY

CAS number

479-92-5

InChI Key

PXWLVJLKJGVOKE-UHFFFAOYSA-N

InChI

InChI=1S/C14H18N2O/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10H,1-4H3

IUPAC Name

1,5-dimethyl-2-phenyl-4-(propan-2-yl)-2,3-dihydro-1H-pyrazol-3-one

SMILES

CC(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1

References

General References

1. TITCK Product Information: Minamol Plus (acetaminophen/caffeine/propyphenazone) oral tablets [Link]

External Links

KEGG Drug

D01380

ChemSpider

3646

RxNav

34710

ChEBI

135538

ChEMBL

CHEMBL28318

ZINC

ZINC000000049151

Wikipedia

Propyphenazone

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
3	Completed	Treatment	Menstrual Distress (Dysmenorrhea)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Capsule
Powder	Oral
Tablet	Oral
Suppository	Rectal
Tablet, coated	Oral
Tablet, film coated	Oral
Suppository
Tablet

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	9.26 mg/mL	ALOGPS
logP	1.94	ALOGPS
logP	2.35	Chemaxon
logS	-1.4	ALOGPS
pKa (Strongest Basic)	0.47	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	23.55 Å2	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	69.92 m3·mol-1	Chemaxon
Polarizability	26.43 Å3	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-001i-0590000000-b45ad15ef4971f839e87
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0fsa-2920000000-5448545b1fe746778dc3
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-001r-0690000000-a62e5f9e1a528954b203
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0910000000-3af6eb80085a93ebcbb4
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-001i-0190000000-d499d58b0fccdbd7758d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-004i-3090000000-c435b95f4582900a2959
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-001i-0090000000-9293361a181f107c8b46
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-001i-5590000000-f839e93bcfb1ec26f8d8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00mp-9760000000-b8e4eade3470fa562e70
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0006-9710000000-f32f5d91c37cc3c301e5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-01x0-9620000000-12621d8a8d8b6fc69380
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	161.18663	predicted	DeepCCS 1.0 (2019)
[M+H]+	163.54463	predicted	DeepCCS 1.0 (2019)
[M+Na]+	169.63777	predicted	DeepCCS 1.0 (2019)

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 23, 2017 20:43 / Updated at September 28, 2021 21:54